Dr. Olalekan Akinyokunbo, M.D Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 400 Cedar St, Metter, GA 30439 Phone: 305-585-1280 |
News Archive
Janssen Inc. has filed a New Drug Submission (NDS) to Health Canada for the investigational drug abiraterone acetate administered with prednisone for the treatment of metastatic, advanced prostate cancer in patients who have received prior chemotherapy containing a taxane. Submissions for abiraterone acetate have also been filed with health authorities in the United States and Europe.
There are two aspects to creating an effective drug: finding a chemical compound that has the desired biological effect and minimal side-effects and then delivering it to the right place in the body for it to do its job.
A review of 21 studies that analyzed the effectiveness of modifying nutritional intake as a treatment for improving sleep found mixed results, as reported in the article "Systematic Review of Dietary Interventions Targeting Sleep Behavior (http://online.liebertpub.com/doi/full/10.1089/acm.2015.0238)" in The Journal of Alternative and Complementary Medicine, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers. The article is available free on The Journal of Alternative and Complementary Medicine (http://online.liebertpub.com/doi/full/10.1089/acm.2015.0238) website until May 21, 2016.
ZaBeCor Pharmaceuticals ("ZaBeCor" or the "Company") announced today the initiation of a Phase II clinical trial for its asthma drug candidate Excellairâ„¢, following the successful results of the Company's Phase I clinical trials. ZaBeCor is one of the first companies to deliver siRNA to the lung and one of the first to target asthma with siRNA.
› Verified 9 days ago